{"id":745098,"date":"2015-10-05T16:15:00","date_gmt":"2015-10-05T16:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/"},"modified":"2025-11-07T01:24:54","modified_gmt":"2025-11-07T06:24:54","slug":"merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/","title":{"rendered":"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment"},"content":{"rendered":"<p class=\"bwalignc\">       Co-recipient Dr. William C. Campbell Conducted his Nobel        Prize-winning Work at Merck Research Laboratories     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      proudly congratulates William C. Campbell, a retired scientist from<br \/>\n      Merck Research Laboratories, who was jointly named the 2015 Nobel Prize<br \/>\n      winner in Physiology or Medicine with Satoshi Omura for the discovery of<br \/>\n      avermectin, which led to Merck\u2019s development of Mectizan (ivermectin), a<br \/>\n      treatment for river blindness (also known as onchocerciasis) in Africa,<br \/>\n      Latin America and Yemen. They will share the prize with Youyou Tu for<br \/>\n      her discoveries concerning a novel therapy against malaria.\n    <\/p>\n<p>\n      River blindness is a parasitic infection that can cause intense itching,<br \/>\n      skin discoloration, rashes, and eye disease that often leads to<br \/>\n      permanent blindness. It is spread by the bites of infected black flies<br \/>\n      that breed in rapidly flowing rivers in the affected countries.\n    <\/p>\n<p>\n      \u201cWe are particularly proud of our colleague Dr. Campbell whose<br \/>\n      innovation, passion and dedication to fighting diseases during his<br \/>\n      30-year career at Merck enabled the development of Mectizan,\u201d said<br \/>\n      Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cThrough our Mectizan Donation Program we have been working with<br \/>\n      partners for nearly three decades to make this medicine available, free<br \/>\n      of charge, to all those affected by river blindness. At Merck, we remain<br \/>\n      committed to bringing the best that our science and innovation have to<br \/>\n      offer to solve the world\u2019s global health challenges.\u201d\n    <\/p>\n<p>\n      Established more than 25 years ago, the Mectizan Donation Program is the<br \/>\n      longest-running disease-specific drug donation program and<br \/>\n      public-private partnership of its kind. In 1998, Merck expanded the<br \/>\n      program to include the elimination of another disease, lymphatic<br \/>\n      filariasis. The program reaches more than 250 million people in the<br \/>\n      affected areas annually, with more than 2 billion treatments donated<br \/>\n      since 1987.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51195118&amp;newsitemid=20151005006695&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=b2edb975ebe71714cfc3aa5d1a84763a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51195118&amp;newsitemid=20151005006695&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=0b212310524570baae358cef3072d05a\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51195118&amp;newsitemid=20151005006695&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=7b094aa7bcea191d5076a8505ed47246\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51195118&amp;newsitemid=20151005006695&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=a37fbeb72bad9ee1e25352cd289893c7\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51195118&amp;newsitemid=20151005006695&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=dc9758e5ca76b7d52d9b05ef10c39be3\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151005006695r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>or<br \/>Claire        Gillespie, 267-305-0932<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck\u2019s development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. They will share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria. River blindness is a parasitic infection that can cause intense itching, skin discoloration, rashes, and eye disease that often leads to permanent blindness. It is spread by the bites of infected black flies that breed in rapidly flowing rivers in the affected countries. \u201cWe are particularly proud of our colleague Dr. Campbell whose<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,54,64,289],"class_list":["post-745098","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-corporate-responsibility-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck\u2019s development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. They will share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria. River blindness is a parasitic infection that can cause intense itching, skin discoloration, rashes, and eye disease that often leads to permanent blindness. It is spread by the bites of infected black flies that breed in rapidly flowing rivers in the affected countries. \u201cWe are particularly proud of our colleague Dr. Campbell whose\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\\\/\",\"name\":\"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-10-05T16:15:00+00:00\",\"dateModified\":\"2025-11-07T06:24:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment - Merck.com","og_description":"Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck\u2019s development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. They will share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria. River blindness is a parasitic infection that can cause intense itching, skin discoloration, rashes, and eye disease that often leads to permanent blindness. It is spread by the bites of infected black flies that breed in rapidly flowing rivers in the affected countries. \u201cWe are particularly proud of our colleague Dr. Campbell whose","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:54+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/","name":"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-10-05T16:15:00+00:00","dateModified":"2025-11-07T06:24:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-awardees-of-2015-nobel-prize-in-physiology-or-medicine-for-discovery-leading-to-river-blindness-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5b47680e-eb11-4d45-af31-2dbc81408a3a","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Congratulates-Awardees-of-2015-Nobel-Prize-in-Physiology-or-Medicine-for-Discovery-Leading-to-River-Blindness-Treatment-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745098\/revisions"}],"predecessor-version":[{"id":3674589,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745098\/revisions\/3674589"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745098"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}